In addition, the CD14+HLA-DRlow/− MDSC count was significantly higher in the CD38high subgroup compared with the CD38low subgroup (P=0.0335; Fig. 2B), the CD14+HLA-DRlow/− MDSC frequency was significantly elevated in the ZAP-70low and ZAP-70high CLL patients when compared with the control group (both P<0.0001), and was significantly higher in the ZAP-70high subgroup compared with ZAP-70low subgroup (P=0.0003) (Fig. 2C). The gene discussed is CD14; the disease is B-cell chronic lymphocytic leukemia.